

# Metabolite profiles and the risk of developing diabetes

Thomas J Wang<sup>1-3</sup>, Martin G Larson<sup>3,4</sup>, Ramachandran S Vasani<sup>3,5</sup>, Susan Cheng<sup>2,3,6</sup>, Eugene P Rhee<sup>1,7,8</sup>, Elizabeth McCabe<sup>2,3</sup>, Gregory D Lewis<sup>1,2,8</sup>, Caroline S Fox<sup>3,9,10</sup>, Paul F Jacques<sup>11</sup>, Céline Fernandez<sup>12</sup>, Christopher J O'Donnell<sup>2,3,8</sup>, Stephen A Carr<sup>8</sup>, Vamsi K Mootha<sup>8,13,14</sup>, Jose C Florez<sup>8,13</sup>, Amanda Souza<sup>8</sup>, Olle Melander<sup>15</sup>, Clary B Clish<sup>8</sup> & Robert E Gerszten<sup>1,2,8</sup>

Emerging technologies allow the high-throughput profiling of metabolic status from a blood specimen (metabolomics). We investigated whether metabolite profiles could predict the development of diabetes. Among 2,422 normoglycemic individuals followed for 12 years, 201 developed diabetes. Amino acids, amines and other polar metabolites were profiled in baseline specimens by liquid chromatography–tandem mass spectrometry (LC-MS). Cases and controls were matched for age, body mass index and fasting glucose. Five branched-chain and aromatic amino acids had highly significant associations with future diabetes: isoleucine, leucine, valine, tyrosine and phenylalanine. A combination of three amino acids predicted future diabetes (with a more than fivefold higher risk for individuals in top quartile). The results were replicated in an independent, prospective cohort. These findings underscore the potential key role of amino acid metabolism early in the pathogenesis of diabetes and suggest that amino acid profiles could aid in diabetes risk assessment.

Metabolic diseases are often present for years before becoming clinically apparent. For instance, by the time relative insulin deficiency manifests as hyperglycemia and a diagnosis of type 2 diabetes is made, considerable pancreatic beta cell insufficiency has already occurred<sup>1</sup>. Current clinical and laboratory predictors such as body mass index or fasting glucose can be helpful in gauging diabetes risk<sup>2</sup>, but they often reflect extant disease, are most useful when assayed in temporal proximity to the development of overt diabetes and may provide little additional insight regarding pathophysiologic mechanisms. Given the availability of effective interventions for delaying or preventing the onset of type 2 diabetes and the increasing burden of the condition worldwide, earlier identification of individuals at risk is particularly crucial<sup>3-6</sup>.

Emerging technologies have made it more feasible to acquire high-throughput profiles of a whole organism's metabolic status (metabolite profiling, or metabolomics)<sup>7-10</sup>. These techniques, which allow assessment of large numbers of metabolites that are substrates and products in metabolic pathways, are particularly relevant for studying metabolic diseases such as diabetes. Furthermore, in addition to serving as potential biomarkers of disease<sup>11</sup>, metabolites may have unanticipated roles as regulatory signals with hormone-like functions<sup>12,13</sup> or effectors of the disease process itself<sup>14</sup>.

Recent cross-sectional studies have documented differences in blood metabolite profiles before and after glucose loading<sup>15-17</sup> and in obese compared with lean individuals<sup>14</sup>. These studies have noted differences in the abundance of C3 and C5 acylcarnitines, glutamine and glutamate, additional amino acids and other small molecules. These observations raise the possibility that alterations in plasma metabolite concentrations could presage the onset of overt diabetes and therefore aid in the identification of at-risk individuals by adding information over standard clinical markers. We performed metabolite profiling in participants from two large, longitudinal studies, with the goal of identifying early pathophysiological changes that might also serve as new predictors of future diabetes.

## RESULTS

### Metabolite profiling in the Framingham Offspring Study

We performed a nested case-control study in the Framingham Offspring Study. Among 2,422 eligible, nondiabetic subjects who underwent a routine examination between 1991 and 1995, 201 individuals developed new-onset diabetes during a 12-year follow-up period (cases). We performed metabolite profiling on the baseline samples from 189 of these individuals, for whom we found 189 propensity-matched control subjects from the same baseline examination who

<sup>1</sup>Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>2</sup>Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>3</sup>Framingham Heart Study of the National Heart, Lung, and Blood Institute and Boston University School of Medicine, Framingham, Massachusetts, USA. <sup>4</sup>Department of Mathematics and Statistics, Boston University, Boston, Massachusetts, USA. <sup>5</sup>Cardiology Section, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA. <sup>6</sup>Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>7</sup>Renal Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>8</sup>Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. <sup>9</sup>Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>10</sup>National Heart, Lung, and Blood Institute, Division of Intramural Research, Bethesda, Maryland, USA. <sup>11</sup>Jean Mayer US Department of Agriculture Human Nutrition Research Center, Tufts University, Boston, Massachusetts, USA. <sup>12</sup>Department of Experimental Medical Science, Lund University, Malmö, Sweden. <sup>13</sup>Diabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>14</sup>Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>15</sup>Department of Clinical Sciences, Lund University, Malmö, Sweden. Correspondence should be addressed to T.J.W. (tjwang@partners.org) or R.E.G. (rgerszten@partners.org).

Received 7 April 2010; accepted 19 January 2011; published online 20 March 2011; doi:10.1038/nm.2307


**Table 1** Baseline characteristics (Framingham Offspring Study)

	Cases ( <i>n</i> = 189)	Matched controls ( <i>n</i> = 189)	Random cohort ( <i>n</i> = 400)
<b>Clinical characteristics</b>			
Age, years	56 ± 9	57 ± 8	55 ± 9
Women, %	42	42	58
Body mass index, kg m <sup>-2</sup>	30.5 ± 5.0	30.0 ± 5.5	26.8 ± 4.6
Waist circumference, cm	102.3 ± 12.1	99.6 ± 13.5	90.8 ± 13.8
Hypertension, %	53	53	27
Parental history of diabetes <sup>a</sup> , %	31	18	21
Physical activity index	35 ± 6.2	35 ± 7.3	35 ± 6.0
Total caloric intake, kcal	1,982 ± 660	1,866 ± 600	1854 ± 581
Total protein intake, g	82 ± 28	78 ± 28	76 ± 26
Phenylalanine intake, g	3.6 ± 1.2	3.4 ± 1.3	3.4 ± 1.1
Tyrosine intake, g	3.0 ± 1.0	2.8 ± 1.1	2.8 ± 1.0
Leucine intake, g	6.5 ± 2.2	6.1 ± 2.3	6.0 ± 2.1
Isoleucine intake, g	3.9 ± 1.3	3.7 ± 1.4	3.6 ± 1.3
Valine intake, g	4.3 ± 1.5	4.1 ± 1.5	4.0 ± 1.4
<b>Other laboratory tests</b>			
Fasting glucose, mg dl <sup>-1</sup>	105 ± 9	105 ± 9	94 ± 9
2-h glucose (OGTT), mg dl <sup>-1</sup>	126 ± 32	118 ± 30	103 ± 27
Serum triglycerides, mg dl <sup>-1</sup>	192 ± 114	151 ± 90	138 ± 93
Fasting insulin, μU ml <sup>-1</sup>	13.7 ± 9.9	11.9 ± 8.8	8.1 ± 7.2
HOMA-IR	3.5 ± 2.6	3.1 ± 2.3	1.9 ± 1.8
HOMA-B	2.7 ± 2.0	2.4 ± 1.7	1.8 ± 1.5

Values are mean ± s.d. or percentage. <sup>a</sup>Parental history information missing in 57 participants.

did not develop diabetes (controls). Cases and controls were closely matched with respect to age, sex, body mass index (BMI) and fasting glucose (Table 1).

We assessed the correlations between baseline concentrations of metabolites. Mean correlations within groups of related molecules were highest for urea cycle metabolites (age- and sex-adjusted  $r = 0.49$ ; Fig. 1),



**Figure 1** Correlation matrix for plasma metabolite levels. Age- and sex-adjusted Pearson correlation coefficients for baseline metabolite values in controls in the Framingham Offspring Study. *cis/trans*-hydroxyproline, *cis*- and *trans*-hydroxyproline; 5-HIAA, 5-hydroxyindoleacetic acid; ADMA/SDMA, asymmetrical and symmetrical dimethylarginine; GABA,  $\gamma$ -aminobutyric acid; NMMA, *N*-monomethyl-arginine.

metabolites involved in nucleotide metabolism ( $r = 0.38$ ), amino acids ( $r = 0.34$ ) and methyl transfer metabolites ( $r = 0.34$ ).

### Selected metabolites predict future diabetes

In paired analyses, five metabolites had  $P$  values of 0.001 or smaller for the baseline differences between cases and controls (Supplementary Table 1). Fasting concentrations were higher in the cases in all instances. Three of these metabolites were branched-chain amino acids: leucine ( $P = 0.0005$ ), isoleucine ( $P = 0.0001$ ) and valine ( $P = 0.001$ ). The other two were aromatic amino acids: phenylalanine ( $P < 0.0001$ ) and tyrosine ( $P < 0.0001$ ). A third aromatic amino acid, tryptophan, had a  $P$  value of 0.003.

The change in concentration of the five branched chain or aromatic amino acids during oral glucose tolerance test (OGTT) was not associated with incident diabetes, suggesting that concentrations after OGTT did not add predictive information to the baseline concentrations. For the other metabolites studied, only lysine showed a differential change with OGTT when cases were compared with controls ( $P = 0.0005$ ).

In additional analyses stratified by duration of follow-up, there was no evidence of an interaction between follow-up year and case-control difference for any of the amino acids ( $P > 0.10$  for all tests of interaction). Thus, the amino acids seemed to retain their predictive value for the development of new-onset diabetes up to 12 years after the baseline examination at which metabolite profiling was performed.

### Predictive value adds to standard clinical measures

We fitted conditional logistic regression models to assess the association between baseline metabolite levels and future diabetes, adjusting for age, sex, BMI and fasting glucose (Table 2). For the five amino acids of interest, each s.d. increment in log marker was associated with a 57–102% increased odds of future diabetes ( $P = 0.0002$ –0.002). Individuals in the top quartile of individual plasma amino acid concentrations had 2- to 3.5-fold higher odds of developing diabetes over the 12-year follow-up period, compared with those whose plasma amino acid levels were in the lowest quartile.

The odds ratios for the metabolites remained strong when we further adjusted the models for parental history of diabetes and serum triglyceride concentrations, which were higher in cases than in controls. Findings were also similar after adjustment for dietary intake of protein, amino acids and total calories, and in the subgroup of individuals with propensity scores in the lowest tertile (data not shown).

Fasting concentrations of the five amino acids moderately correlated with biochemical measures of insulin resistance and beta cell function, including homeostatic model assessment of insulin resistance

**Table 2** Relation of baseline amino acid concentrations to risk of future diabetes (Framingham Offspring Study)

Model	Isoleucine	Leucine	Valine	Tyrosine	Phenylalanine	Isoleucine, tyrosine and phenylalanine
<b>Models adjusting for age, sex, BMI and fasting glucose (n = 378)</b>						
Metabolite as continuous variable						
Per s.d.	1.70 (1.27–2.28)	1.62 (1.20–2.17)	1.57 (1.17–2.09)	1.85 (1.35–2.55)	2.02 (1.40–2.92)	2.42 (1.66–3.54)
P	0.0004	0.001	0.002	0.0001	0.0002	<0.0001
Metabolite as categorical variable						
First quartile	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
Second quartile	1.11 (0.58–2.10)	2.40 (1.24–4.68)	1.49 (0.75–2.94)	1.89 (0.94–3.81)	1.39 (0.74–2.59)	3.48 (1.68–7.23)
Third quartile	2.14 (1.07–4.27)	3.15 (1.46–6.84)	2.15 (1.05–4.42)	3.26 (1.56–6.84)	2.12 (1.04–4.32)	2.82 (1.25–6.34)
Fourth quartile	3.14 (1.51–6.55)	3.66 (1.61–8.29)	3.14 (1.43–6.86)	2.82 (1.25–6.34)	2.28 (1.00–5.20)	5.99 (2.34–15.34)
P for trend	0.001	0.004	0.003	0.010	0.035	0.0009
<b>Models adjusting for age, sex, BMI, fasting glucose and parental history (n = 272)</b>						
Metabolite as continuous variable						
Per SD	1.70 (1.19–2.44)	1.67 (1.16–2.40)	1.54 (1.07–2.22)	2.02 (1.34–3.05)	2.01 (1.29–3.12)	2.62 (1.61–4.28)
P	0.004	0.006	0.02	0.0008	0.002	0.0001
Metabolite as categorical variable						
First quartile	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
Second quartile	0.92 (0.41–2.09)	1.95 (0.84–4.52)	0.94 (0.39–2.29)	1.64 (0.71–3.79)	1.39 (0.64–2.99)	4.60 (1.72–12.32)
Third quartile	1.62 (0.68–3.85)	2.99 (1.13–7.90)	1.89 (0.78–4.56)	3.26 (1.29–8.24)	2.07 (0.84–5.08)	3.69 (1.16–11.78)
Fourth quartile	2.98 (1.21–7.38)	4.12 (1.51–11.30)	2.85 (1.06–7.65)	2.91 (1.03–8.25)	2.10 (0.76–5.78)	7.60 (2.14–27.07)
P for trend	0.009	0.006	0.012	0.034	0.134	0.007

Values are odds ratios (95% confidence intervals) for diabetes from conditional logistic regressions. All models are adjusted for age, sex, BMI and fasting glucose. The amino acid combination is modeled according to the formula  $\beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3$ , with  $X_j$  denoting the standardized value for the  $j$ th amino acid and  $\beta_j$  denoting the regression coefficient from the regression model containing the indicated metabolites.

(HOMA-IR) and homeostatic model assessment of beta cell function (HOMA-B) ( $r = 0.24$ – $0.37$ ,  $P < 0.001$ ; **Supplementary Table 2**). Nonetheless, the association of the plasma amino acid concentrations and incident diabetes was unchanged even after adjusting for these measures (**Table 3**).

### Amino acid combinations and prediction of diabetes

We assessed the predictive performance of clinical models containing fasting plasma amino acids (**Supplementary Table 3**). The basic clinical model had a  $-2$ -log likelihood ratio (LHR statistic)  $< 3$ , which was expected given the matched-pair design that included age, sex, BMI and fasting glucose. Addition of any one of the five branched chain or aromatic amino acids improved the model fit substantially, as indicated by large increases in the LHR statistic ( $+9$ – $16$ ,  $P < 0.05$ ). Combinations of three amino acids further improved the  $-2$ -log likelihood ratio ( $+6$  to  $9$ ,  $P < 0.05$ ), when compared with individual amino acids. There was only small additional increment in the LHR statistic when all five amino acids were included. We observed similar patterns with changes in the  $c$ -statistic across different models. The top combination of three amino acids on the basis of LHR statistic and  $c$ -statistic comprised isoleucine, phenylalanine and tyrosine.

We performed conditional logistic regression models with the three-amino-acid combination (isoleucine, phenylalanine

and tyrosine). Individuals in the top quartile of the amino acid score had a five- to sevenfold higher risk of developing diabetes compared with individuals in the lowest quartile ( $P$  for trend,  $0.007$ – $0.0009$ ; **Table 2**).

### Replication analyses (Malmö Diet and Cancer study)

We measured the five amino acids of interest in an independent replication sample from the Malmö Diet and Cancer study comprising 163 cases and 163 controls (mean age 58 years, 55% women). Four of the five individual amino acids (leucine, valine, tyrosine and phenylalanine) were significantly associated with incident diabetes (adjusted odds ratios per s.d. increment were similar to Framingham, 1.37 to 2.01;  $P = 0.009$  to  $0.04$ ; **Table 4**). The remaining amino acid, isoleucine, had a nonsignificant association ( $P = 0.09$ ).

We also tested the three-amino acid combination (isoleucine, phenylalanine and tyrosine) derived in the Framingham Offspring Study. Individuals in the upper quartile of the three-amino acid combination had a fourfold higher risk of incident diabetes in the Malmö Diet and Cancer study compared with those in the lowest quartile ( $P$  for trend across quartiles,  $0.006$ ; **Table 4**).

### Assessment of biomarkers in a random population

Because diabetes propensity was used to match individuals in the case-control studies, the study sample was enriched for individuals

**Table 3** Relation of individual amino acid concentrations to risk of future diabetes, with adjustment for insulin measures

Model	Isoleucine	Leucine	Valine	Tyrosine	Phenylalanine
<b>Adjusted odds ratios, per s.d. increment in metabolite (95% confidence interval)</b>					
Basic model	1.70 (1.27–2.28)	1.62 (1.20–2.17)	1.57 (1.17–2.09)	1.85 (1.35–2.55)	2.02 (1.40–2.92)
+ fasting insulin	1.65 (1.23–2.23)	1.58 (1.17–2.12)	1.52 (1.13–2.04)	1.81 (1.31–2.50)	2.00 (1.38–2.89)
+ HOMA-IR	1.65 (1.23–2.23)	1.58 (1.17–2.12)	1.52 (1.13–2.04)	1.81 (1.31–2.50)	2.00 (1.39–2.89)
+ HOMA-B	1.65 (1.23–2.23)	1.58 (1.17–2.12)	1.52 (1.13–2.04)	1.81 (1.31–2.50)	2.00 (1.38–2.88)
+ OGTT (2-h glucose)	1.60 (1.18–2.17)	1.53 (1.13–2.06)	1.49 (1.11–2.00)	1.79 (1.30–2.47)	1.98 (1.37–2.86)

Basic model: age, sex, BMI and fasting glucose. Subsequent models include the basic clinical variables plus the insulin resistance or sensitivity measure indicated.

**Table 4 Replication in the Malmö Diet and Cancer study**

Model	Isoleucine	Leucine	Valine	Tyrosine	Phenylalanine	Isoleucine, tyrosine and phenylalanine
Metabolite as continuous variable						
Per s.d.	1.37 (0.95–1.96)	1.60 (1.13–2.27)	2.01 (1.18–3.42)	1.41 (1.05–1.91)	1.37 (1.01–1.84)	1.52 (1.10–2.11)
<i>P</i>	0.09	0.009	0.01	0.02	0.04	0.01
Metabolite as categorical variable						
First quartile	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
Second quartile	1.02 (0.53–1.98)	1.97 (0.86–4.54)	2.11 (0.99–4.48)	1.92 (0.92–4.01)	2.37 (1.08–5.16)	2.08 (0.97–4.46)
Third quartile	1.62 (0.77–3.42)	2.53 (1.09–5.87)	1.82 (0.59–5.65)	2.17 (1.03–4.57)	4.30 (1.87–9.88)	2.59 (1.09–6.15)
Fourth quartile	2.37 (0.97–5.81)	3.81 (1.39–10.46)	2.85 (0.77–10.51)	3.16 (1.31–7.59)	3.04 (1.20–7.70)	3.93 (1.54–10.04)
<i>P</i> for trend	0.05	0.01	0.09	0.01	0.007	0.006

Values are odds ratios (95% confidence intervals) for diabetes, from conditional logistic regressions. All models are adjusted for age, sex, BMI and fasting glucose. The amino acid combination is modeled according to the formula  $\beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3$ , with  $X_j$  denoting the standardized value for the  $j$ th amino acid and  $\beta_j$  denoting the regression coefficient from the conditional logistic regression model containing the indicated metabolites.

with high-risk features such as obesity and elevated fasting glucose. As a consequence, the results in the case-control samples reflect what would be expected in a high-risk cohort but not necessarily in a more heterogeneous sample. Thus, we performed metabolomic profiling on an additional 400 controls randomly selected from all individuals in the Framingham Offspring cohort who were free of diabetes or cardiovascular disease ( $n = 2,422$ ). As expected, the new sample (referred to as the random cohort) had a lower mean fasting glucose and BMI compared with the original case-control sample (Table 1).

We repeated the analyses for the amino acid profiles identified in the case-control study. After adjustment for standard diabetes risk factors, including fasting glucose, BMI and parental history, the amino acid profile was still associated with future diabetes development (adjusted odds ratio, 1.36, per s.d. increment in the amino acid score,  $P = 0.008$ ; Table 5 and Supplementary Table 3). Individuals with the highest amino acid scores (top quartile) had an approximately twofold higher adjusted risk of developing diabetes over 12 years of follow-up.

**Table 5 Results for the amino acid combination in the random cohort sample**

Model	Three amino acids (isoleucine, phenylalanine and tyrosine)	Five amino acids (isoleucine, phenylalanine, tyrosine, leucine and valine)
<b>Models adjusting for age, sex, BMI and fasting glucose (<math>n = 601</math>)</b>		
Per s.d. (score)	1.33 (1.08–1.63)	1.33 (1.08–1.63)
<i>P</i>	0.008	0.007
First quartile	1.0 (referent)	1.0 (referent)
Second quartile	1.12 (0.64–1.98)	1.07 (0.60–1.90)
Third quartile	1.43 (0.81–2.53)	1.67 (0.95–2.95)
Fourth quartile	1.73 (0.96–3.10)	1.94 (1.08–3.49)
<i>P</i> for trend	0.03	0.005
<b>Models adjusting for age, sex, BMI, fasting glucose and parental history (<math>n = 516</math>)</b>		
Per s.d. (score)	1.36 (1.08–1.70)	1.38 (1.09–1.74)
<i>P</i>	0.008	0.007
First quartile	1.0 (referent)	1.0 (referent)
Second quartile	1.42 (0.73–2.73)	1.48 (0.76–2.89)
Third quartile	1.93 (1.00–3.71)	2.16 (1.11–4.20)
Fourth quartile	2.01 (1.02–3.99)	2.23 (1.12–4.42)
<i>P</i> for trend	0.03	0.01

Values are odds ratios (95% confidence intervals) for diabetes, from conditional logistic regressions. The amino acid combination is modeled according to the formula  $\beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3$ , with  $X_j$  denoting the standardized value for the  $j$ th amino acid and  $\beta_j$  denoting the regression coefficient from the conditional logistic regression model containing the indicated metabolites.

## DISCUSSION

Using a mass spectrometry-based metabolite profiling platform, we identified a panel of amino acids whose fasting concentrations at a routine examination predicted the future development of diabetes in otherwise healthy, normoglycemic individuals. Indeed, fasting concentrations of these amino acids were elevated up to 12 years before the onset of diabetes. The risk of future diabetes was elevated at least fourfold in those with high plasma amino acid concentrations in both the discovery and replication samples.

A growing number of studies have used mass spectrometry as a tool for biomarker discovery<sup>18,19</sup>, but these studies have been largely cross-sectional, providing limited information regarding the relation of metabolomic (or proteomic) biomarkers to the future development of disease. Thus, a strength of our investigation is the use of two well-characterized prospective cohorts, one for derivation and one for replication, each with more than 3,000 participants who have been followed longitudinally for decades. All individuals in our study were free of diabetes at the time the blood samples were collected, and matching for BMI and fasting blood glucose in our study design minimized confounding from existing glucose intolerance. The long period of observation enabled us to show that circulating amino acid elevations can occur well before any alteration in insulin action is detectable by standard biochemical measures.

Our findings, which highlight five branched-chain and aromatic amino acids from 61 metabolites profiled, are noteworthy in the context of experimental and clinical data suggesting that certain amino acids may be both markers and effectors of insulin resistance<sup>14,15,18,20,21</sup>. Several decades ago, a study of 20 nonobese and obese individuals found that fasting concentrations of branched-chain and aromatic amino acids correlated with obesity and serum insulin<sup>20</sup>. Additionally, glucose loading lowered amino acid concentrations in insulin-sensitive, but not insulin-resistant, individuals. Both sets of findings have been corroborated by more recent studies using LC-MS-based metabolomics platforms<sup>14–16,18</sup>. Studies of branched-chain amino acid supplementation in both animals<sup>14</sup> and humans<sup>22</sup> indicate that circulating amino acids may directly promote insulin resistance, possibly via disruption of insulin signaling in skeletal muscle. The underlying cellular mechanisms may include activation of the mammalian target of rapamycin, JUN and insulin receptor substrate-1 signaling pathways in skeletal muscle<sup>14,21</sup>. By contrast, others have shown improved glucose homeostasis in mice fed a diet specifically enriched in leucine<sup>23</sup>.

In addition to insulin resistance, impaired insulin secretion has a crucial role in the pathogenesis of type 2 diabetes. In this regard, it is noteworthy that multiple amino acids, particularly the

branched-chain amino acids, are modulators of insulin secretion<sup>24–26</sup>. Thus, another possible mechanism by which hyperaminoacidemia could promote diabetes is via hyperinsulinemia leading to pancreatic beta cell exhaustion.

Although circulating amino acids correlated with standard biochemical measures of insulin resistance and beta cell function, amino acid concentrations were predictive even among individuals with similar fasting insulin and glucose concentrations. Furthermore, stimulation of the insulin axis with OGTT did not elicit differential amino acid changes between cases and controls. All of these findings support the notion that hyperaminoacidemia could be a very early manifestation of insulin resistance—one that presages the clinical onset of diabetes by years.

The ability to identify individuals before the onset of disease is particularly important for conditions such as diabetes, because proven, preventive therapies exist and end-organ complications accrue over time. Although traditional risk factors such as BMI and fasting glucose provide key information about future diabetes risk, not all individuals who are obese develop diabetes. It is crucial to understand which at-risk individuals are most likely to progress to overt disease. There has been interest in genetic risk prediction, but the known diabetes polymorphisms add modestly to risk assessment<sup>27,28</sup>. For instance, known polymorphisms are associated with only 5–37% increases in the relative risk of diabetes, compared with the 60–100% increases in risk that we observed with elevation in amino acids. Indeed, the relative risks associated with elevated amino acids were comparable to, or higher than, those associated with higher age, fasting glucose or body mass index in previous population-based studies<sup>28</sup>.

Additionally, our findings may provide insight regarding subgroups in which amino profiles could yield the most incremental information. Most of our analyses were based on high-risk study samples as a result of the matching scheme that paired cases with controls who had a high predicted risk of diabetes. In this setting, amino acid elevations were associated with very high relative risks for developing diabetes, and the amino acid profiles led to large improvements in model fit and discrimination (*c* statistics). We found this result in both the discovery and replication cohorts, attenuating concern for overfitting of the data. In a more heterogeneous study sample, obtained by looking at a random set of controls from the Framingham cohort, the relative risks associated with elevated amino acids were attenuated (though still significant, in the twofold range), and changes in *c* statistics were modest. Baseline BMI and glucose concentrations in the random cohort analysis were lower, on average, compared with the case-control analyses, and the distributions much broader. Most of the variation in diabetes risk in such a sample is attributable to variation in BMI and other standard diabetes risk factors. Overall, these findings suggest that amino acid profiling might have greater value in high-risk individuals, but confirmation in additional studies is needed.

Several limitations of the study deserve comment. We used a targeted approach that coupled liquid chromatography with a triple quadrupole tandem mass spectrometer. Although alternate LC-MS techniques or nuclear magnetic resonance spectroscopy can be used to acquire spectral data in a less biased manner, targeted LC-MS provides much greater sensitivity, highly specific identification of analytes and the ability to quantify absolute analyte concentrations when appropriate standards are added. The platform used for our study was geared toward small molecules such as amino acids, as well as urea-cycle and nucleotide metabolites. This choice was informed by previous studies suggesting a cross-sectional association between insulin resistance and several

metabolites<sup>18,20</sup> and the absence of prospective data linking metabolite concentrations to future risk of diabetes. Our identification of a set of five amino acids whose fasting levels strongly predict the future development of diabetes does not preclude that other metabolites may also predict disease. Identification of new biomarkers will no doubt accelerate as platforms expand their metabolite coverage.

In the Framingham Offspring Study, close surveillance of the participants over serial examinations ensured reliable ascertainment of the development of diabetes over time. In the replication cohort (Malmö Diet and Cancer study), incident diabetes cases were identified through the use of three registries. Although this introduces the possibility of misclassification of diabetes status in the Malmö Diet and Cancer study, such misclassification would be expected to bias the results toward the null. Indeed, the robustness of the findings in two longitudinal cohorts with widely different methods for ascertaining diabetes further increases our confidence in the validity of the results. Lastly, individuals in both cohorts were predominantly white and of European descent. Further studies are needed to determine whether the findings extend to other racial and ethnic groups.

In summary, from a panel of > 60 metabolites, branched-chain and aromatic amino acids emerged as predictors of the future development of diabetes. A single, fasting measurement of these amino acids provided information over standard risk factors (such as BMI, dietary patterns and fasting glucose). Further investigation is warranted to test whether plasma amino acid measurements might help identify candidates for interventions to reduce diabetes risk and to elucidate the biological mechanisms by which certain amino acids might promote type 2 diabetes.

## METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturemedicine/>.

*Note: Supplementary information is available on the Nature Medicine website.*

## ACKNOWLEDGMENTS

This work was supported by US National Institutes of Health contract NO1-HC-25195, R01-DK-HL081572, the Donald W. Reynolds Foundation, the Leducq Foundation and the American Heart Association. S.C. is also supported by an award from the Ellison Foundation. J.C.F. is also supported by the Massachusetts General Hospital and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation.

## AUTHOR CONTRIBUTIONS

T.J.W. conceived of the study, designed the experiments, analyzed and interpreted the data and wrote the manuscript. A.S. and E.P.R., under the direction of C.B.C., developed the metabolic profiling platform, performed mass spectrometry experiments and analyzed the data. S.A.C. and V.K.M. helped in the establishment of the metabolite profiling platform and manuscript revision. G.D.L. contributed to data analysis and manuscript generation. M.G.L., R.S.V., S.C. and E.M. helped in experimental design, performed statistical analyses and assisted in manuscript generation. C.J.O. and C.S.F. helped in experimental design and manuscript revision. P.F.J. directed the dietary analyses in the Framingham Heart Study and contributed to manuscript revision. J.C.F. assisted in the interpretation of the data and contributed to manuscript revision. O.M. and C.F. performed the replication analyses in the Malmö Diet and Cancer cohort and contributed to manuscript revision. R.E.G. conceived of the study, designed the experiments, analyzed and interpreted the data and wrote the manuscript.

## COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturemedicine/>.

Published online at <http://www.nature.com/naturemedicine/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

1. Tabák, A.G. *et al.* Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. *Lancet* **373**, 2215–2221 (2009).
2. Wilson, P.W. *et al.* Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. *Arch. Intern. Med.* **167**, 1068–1074 (2007).
3. Pan, X.R. *et al.* Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* **20**, 537–544 (1997).
4. Tuomilehto, J. *et al.* Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N. Engl. J. Med.* **344**, 1343–1350 (2001).
5. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* **346**, 393–403 (2002).
6. Gerstein, H.C. *et al.* Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet* **368**, 1096–1105 (2006).
7. Nicholson, J.K. & Wilson, I.D. Opinion: understanding 'global' systems biology: metabolomics and the continuum of metabolism. *Nat. Rev. Drug Discov.* **2**, 668–676 (2003).
8. Raamsdonk, L.M. *et al.* A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. *Nat. Biotechnol.* **19**, 45–50 (2001).
9. Allen, J. *et al.* High-throughput classification of yeast mutants for functional genomics using metabolic footprinting. *Nat. Biotechnol.* **21**, 692–696 (2003).
10. An, J. *et al.* Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. *Nat. Med.* **10**, 268–274 (2004).
11. Sabatine, M.S. *et al.* Metabolomic identification of novel biomarkers of myocardial ischemia. *Circulation* **112**, 3868–3875 (2005).
12. Sapieha, P. *et al.* The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. *Nat. Med.* **14**, 1067–1076 (2008).
13. He, W. *et al.* Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. *Nature* **429**, 188–193 (2004).
14. Newgard, C.B. *et al.* A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab.* **9**, 311–326 (2009).
15. Shaham, O. *et al.* Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. *Mol. Syst. Biol.* **4**, 214 (2008).
16. Wopereis, S. *et al.* Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. *PLoS ONE* **4**, e4525 (2009).
17. Zhao, X. *et al.* Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? *Am. J. Physiol. Endocrinol. Metab.* **296**, E384–E393 (2009).
18. Huffman, K.M. *et al.* Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. *Diabetes Care* **32**, 1678–1683 (2009).
19. Lewis, G.D., Asnani, A. & Gerszten, R.E. Application of metabolomics to cardiovascular biomarker and pathway discovery. *J. Am. Coll. Cardiol.* **52**, 117–123 (2008).
20. Felig, P., Marliss, E. & Cahill, G.F. Jr. Plasma amino acid levels and insulin secretion in obesity. *N. Engl. J. Med.* **281**, 811–816 (1969).
21. Patti, M.E., Brambilla, E., Luzi, L., Landaker, E.J. & Kahn, C.R. Bidirectional modulation of insulin action by amino acids. *J. Clin. Invest.* **101**, 1519–1529 (1998).
22. Krebs, M. *et al.* Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. *Diabetes* **51**, 599–605 (2002).
23. Zhang, Y. *et al.* Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. *Diabetes* **56**, 1647–1654 (2007).
24. Floyd, J.C. Jr. Fajans, S.S., Conn, J.W., Knopf, R.F. & Rull, J. Stimulation of insulin secretion by amino acids. *J. Clin. Invest.* **45**, 1487–1502 (1966).
25. Nilsson, M., Holst, J.J. & Bjorck, I.M. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. *Am. J. Clin. Nutr.* **85**, 996–1004 (2007).
26. van Loon, L.J., Saris, W.H., Verhagen, H. & Wagenmakers, A.J. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *Am. J. Clin. Nutr.* **72**, 96–105 (2000).
27. Meigs, J.B. *et al.* Genotype score in addition to common risk factors for prediction of type 2 diabetes. *N. Engl. J. Med.* **359**, 2208–2219 (2008).
28. Lyssenko, V. *et al.* Clinical risk factors, DNA variants, and the development of type 2 diabetes. *N. Engl. J. Med.* **359**, 2220–2232 (2008).

## ONLINE METHODS

**Study samples.** The Framingham Offspring Study was initiated in 1971, when 5,124 individuals enrolled into a longitudinal cohort study<sup>29</sup>. The fifth quadrennial examination took place between 1991 and 1995. Of 3,799 attendees to the fifth examination, 2,422 were eligible for our investigation because they were free of diabetes and cardiovascular disease, underwent routine OGTT and were 35 years old or older.

We tested findings for replication in the Malmö Diet and Cancer study, a Swedish population-based cohort of 28,449 persons enrolled between 1991 and 1996. From this cohort, 6,103 persons were randomly selected to participate in the Malmö Diet and Cancer Cardiovascular Cohort<sup>30</sup>. We obtained fasting plasma samples in 5,305 subjects in the Malmö Diet and Cancer Cardiovascular Cohort, of whom 564 had prevalent diabetes or cardiovascular disease before baseline and an additional 456 subjects had missing covariate data, leaving 4,285 subjects eligible for analysis.

The study protocols were approved by the Institutional Review Boards of Boston University Medical Center, Massachusetts General Hospital and Lund University, Sweden, and all participants provided written informed consent. Detailed descriptions of the clinical assessment, diabetes definition and subject selection are provided in the **Supplementary Methods**.

**Metabolite profiling.** We profiled amino acids, biogenic amines and other polar plasma metabolites by LC-MS. Formic acid, ammonium acetate, LC-MS-grade solvents and valine-d8 were purchased from Sigma-Aldrich. We purchased the remainder of the isotopically labeled analytical standards from Cambridge Isotope Labs. We prepared calibration curves for a subset of the profiled analytes by serial dilution in stock pooled plasma using stable isotope-labeled reference compounds (leucine-<sup>13</sup>C, 15N, isoleucine-<sup>13</sup>C6, 15N, alanine-<sup>13</sup>C, glutamic acid-<sup>13</sup>C5, 15N, taurine-<sup>13</sup>C2, trimethylamine-N-oxide-d9). We ran samples with isotope standards for calibration curves at the beginning, middle and end of each analytical queue. We prepared plasma samples for LC-MS analyses via protein precipitation with the addition of nine volumes of 74.9:24.9:0.2 vol/vol/vol acetonitrile/methanol/formic acid containing two additional stable isotope-labeled internal standards for valine-d8 and phenylalanine-d8. The samples were centrifuged (10 min, 15,000g, 4 °C), and the supernatants were injected directly. Detailed methods are provided in the **Supplementary Methods**.

**Statistical analyses.** We examined the association between plasma metabolite concentrations (before and after OGTT) and incident diabetes in Framingham. We log-transformed metabolite levels because the case-control differences did not show a constant variance. We compared cases (those developing new-onset diabetes during the 12-year follow-up) versus propensity-matched controls, using paired *t* tests for the 48 metabolites with <5% missing data. For the 13 metabolites with undetectable levels in ≥5% of samples, we used McNemar's test to compare the proportion of detectable values. We also examined whether the change in metabolite levels during OGTT was associated with diabetes, by regressing the 2-h metabolite level on the baseline level, case status, and an interaction term, using generalized estimating equations.

We used a corrected *P* value threshold of 0.001 to account for the 48 metabolites analyzed as continuous variables (**Supplementary Methods**). For metabolites meeting the *P* value threshold, we performed conditional (matched-pairs) logistic regression analyses to estimate the relative risk of diabetes at different metabolite values, adjusting for age, sex, BMI and fasting glucose. In additional analyses, we also adjusted for parental history, serum triglycerides, high-density lipoprotein cholesterol, hypertension, intake of dietary protein, amino acids and total calories. We also assessed whether plasma metabolites predicted diabetes risk incrementally over biochemical measures of insulin resistance and beta cell function: fasting insulin, HOMA-IR, HOMA-B and glucose 2 h after OGTT<sup>31</sup>. These models were adjusted for age, sex, BMI, fasting glucose and the log-transformed insulin resistance or secretion measure. We analyzed metabolites as both continuous and categorical (using the quartile values in controls as cutpoints) variables. We also performed secondary analyses restricted to case-control pairs in the lowest tertile of propensity score.

To identify the most predictive biomarker combination, we calculated log-likelihood ratios and evaluated model discrimination using the *c* statistic. The *c* statistic was calculated by assessing the proportion of case-control pairs for which the biomarker value in cases exceeded that in controls. We assessed biomarker combinations by calculating the sum of standardized biomarker values weighted according to their corresponding beta coefficients from the regression analyses and entering the weighted value into a separate logistic regression model. The values were grouped into quartiles and tested using a class variable to estimate the odds ratio for each quartile.

We attempted to replicate our findings in the Malmö Diet and Cancer cohort by testing the most significant metabolite predictors identified in the Framingham cohort. A replication *P* value <0.05 was considered significant. We also performed analyses in a random cohort sample from the Framingham cohort to assess the association between amino acids and diabetes risk in a lower-risk, more heterogeneous group. A total of 201 cases were available for this analysis (overall *n* = 601). We used Cox proportional hazards models to account for time to diabetes onset (discrete time based on interexamination interval), with adjustment for age, sex, BMI, fasting glucose, parental diabetes history and metabolite scores as described above.

**Additional methods.** Detailed methodology is described in the **Supplementary Methods, Supplementary Figure 1 and Supplementary Table 4**.

29. Kannel, W.B., Feinleib, M., McNamara, P.M., Garrison, R.J. & Castelli, W.P. An investigation of coronary heart disease in families: the Framingham Offspring Study. *Am. J. Epidemiol.* **110**, 281–290 (1979).
30. Persson, M., Hedblad, B., Nelson, J.J. & Berglund, G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. *Arterioscler. Thromb. Vasc. Biol.* **27**, 1411–1416 (2007).
31. Matthews, D.R. *et al.* Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* **28**, 412–419 (1985).